CAVA Group earnings outlook: options market prices in 11% swing
CAVA Group’s implied volatility rose to 76.54% ahead of earnings, with options pricing an 11% stock swing for Aug 11. Shares trade around $63.05. Valuation metrics include LTM P/E 51.2 and forward P/E 110.5, with FY2025 revenue growth 22.4% and FY2026 forecast 27.1%. Analyst fair value is $64.37 and mean target $91.29.
How this was made
The 30-second read
Why it matters
Traders can use the options-implied 11% swing and elevated IV percentile to size risk and plan for post-earnings volatility, while recognizing that skew indicates mixed positioning and uncertain direction.
Market read
Options markets are signaling unusually large earnings-driven volatility for CAVA, but the direction is not consensus.
What to watch
Direction uncertainty from skew can reflect hedging demand rather than true bearishness; guidance quality and margin trajectory matter more than the options mix.
Background
The piece frames CAVA’s upcoming earnings as a high-expectation, high-volatility event, using options-implied metrics and valuation context.
Ticker impact
CAVA’s implied volatility jumped to 76.54% and options price an 11% earnings swing ahead of its Aug 11 report.
Expect elevated post-earnings volatility; direction likely hinges on guidance and margin commentary.
The article cites a large IV percentile jump, a sizable 11% implied move, and mixed put and call positioning, implying hedging plus speculation rather than a clear directional consensus.
Market effects
Highlights heightened risk sensitivity in fast-casual/restaurant names tied to FDA-related headlines, which can spill into peers’ earnings expectations.
Primarily US-listed equity options positioning; limited direct regional spillover beyond US consumer/restaurant sentiment.
Low direct global relevance; mostly a US earnings-volatility setup.
Counterpoint
The 11% implied move may already be priced; if results are merely in-line, CAVA could mean-revert despite the high IV.
Key entities
- public_companyCAVA Group, Inc.
Subject of the article, with options-implied volatility and earnings-swing expectations ahead of its Aug 11 earnings.
- regulatory_health_eventFDA cyclosporiasis outbreak (sector headline)
Mentioned as a recent sector health scare that contributed to sharp moves in the group, including CAVA’s one-month decline.
